Seminars in Oncology
Volume 33, Issue 5 , Pages 563-575, October 2006

Prognostic Factors in Renal Cell Carcinoma

  • Brian M. Shuch

      Affiliations

    • Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA.
  • ,
  • John S. Lam

      Affiliations

    • Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA.
    • Corresponding Author InformationAddress correspondence to John S. Lam, MD, Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, 10833 Le Conte Ave, 66-118 CHS, Box 951738, Los Angeles, CA 90095, USA.
  • ,
  • Arie S. Belldegrun

      Affiliations

    • Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA.
  • ,
  • Robert A. Figlin

      Affiliations

    • Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA.
    • Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Beckman Research Institute, and Comprehensive Cancer Center, Duarte, CA.

The identification of prognostic factors in patients with renal cell carcinoma (RCC) represents an area of increasing interest. The tumor, node, metastasis (TNM) staging system is currently the most extensively used tool for providing prognostic information for RCC. Data published in the last few years have led to significant controversies as to whether further revisions are needed in current staging systems and whether improvements can be made with the introduction of new, more accurate and predictive prognostic factors not currently included in traditional staging systems. While integrated staging systems have improved the staging of RCC, the recent discovery of molecular tumor markers is expected to revolutionize the staging of RCC in the future and lead to the development of new therapies based on molecular targeting. The aim of the current review is to highlight such controversies and provide an update on current staging modalities and prognostic factors for RCC.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by the Richard and Nancy Bloch Kidney Cancer Research Fund.

PII: S0093-7754(06)00272-7

doi:10.1053/j.seminoncol.2006.06.006

Seminars in Oncology
Volume 33, Issue 5 , Pages 563-575, October 2006